Immix Biopharma Reports 95% Complete Response Rate in Relapsed/Refractory AL Amyloidosis Trial
Immix Biopharma (IMMX) announced a 95% complete response rate among the first 20 patients treated with NXC-201 in its clinical trial for relapsed/refractory AL amyloidosis. All CRs were achieved within one year of dosing, and no relapses have been observed so far.
Tickers: $IMMX
Topics: al amyloidosis biopharma mrD-negative nxc-201